Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

The effect of anti-CD40 ligand in immune thrombocytopenic purpura.

Authors: Patel, VL  Schwartz, J  Bussel, JB 
Citation: Patel VL, etal., Br J Haematol. 2008 May;141(4):545-8. doi: 10.1111/j.1365-2141.2008.07039.x. Epub 2008 Mar 12.
Pubmed: (View Article at PubMed) PMID:18341638
DOI: Full-text: DOI:10.1111/j.1365-2141.2008.07039.x

Immune thrombocytopenic purpura (ITP) is mediated by antiplatelet autoantibodies possibly involving CD40:CD40L co-stimulation. Two humanized anti-CD40L monoclonal antibodies, hu5c8 and IDEC-131, were evaluated in 46 patients with chronic refractory ITP. Fifteen patients were treated with 20 mg/kg of hu5c8: four (27%) had complete responses (CR) and two (13%) had partial responses (PR). Three responders to hu5c8 were successfully retreated with IDEC-131, demonstrating its efficacy. Thirty-one subsequent patients were treated with 5-20 mg/kg per infusion of IDEC-131: five (16%) responded (one CR and four PR). The 24% (11/46) overall response rate demonstrates the potential role of CD40-CD40L in the pathogenesis of ITP.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11352237
Created: 2016-07-12
Species: All species
Last Modified: 2016-07-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.